Status:
UNKNOWN
Patient-centred Smartphone AI for Protecting Vision in Macular Disease
Lead Sponsor:
OKKO Health
Collaborating Sponsors:
INNOVATEUK
Nottingham University Hospitals NHS Trust
Conditions:
Age-Related Macular Degeneration
Eligibility:
All Genders
Brief Summary
Macular disease is the leading cause of blindness in the UK and age-related macular degeneration must undergo monitoring to determine if an injection into the eye is required that month \[required in ...
Detailed Description
The OKKO Health application is a CE-marked medical software application that aims to monitor visual function, track symptoms and treatment, and improve patient knowledge about their condition. To mon...
Eligibility Criteria
Inclusion
- Patients newly diagnosed with wet (neovascular) AMD in at least on eye at the start of their anti-VGEF treatment.
- Participants with wet AMD in at least one eye undergoing anti-VGEF therapy.
- Access to a device running a compatible software
- Apple device running iOS 12 or later,
- Android devices running Android 7.0 or later,
- Ability to read and understand English.
- Willing and able to provide informed consent.
Exclusion
- Vision worse than 6/60 or 1.0 LogMAR in both eyes.
- Significant cognitive impairment.
- Patients who do not have the manual dexterity to tap a screen.
Key Trial Info
Start Date :
March 8 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2024
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05433766
Start Date
March 8 2023
End Date
April 1 2024
Last Update
March 10 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom, NG7 2UH
2
Oxford University Hospitals NHS Trust
Oxford, United Kingdom, OX3 9DU